Immunotherapy in Melanoma | Specialty

ESMO 2019: Dr. Spigel Highlights Progress in Lung Cancer

September 29th 2019

ESMO 2019: Dr. Rugo Highlights Progress in Breast Cancer

September 29th 2019

ESMO 2019: Dr. O'Shaughnessy Highlights Progress in Breast Cancer

September 29th 2019

ESMO 2019: Dr. Choueiri Discusses Novel Treatment Strategies in GU Cancers

September 29th 2019

ESMO 2019: Dr. Hamid Discusses Exciting Immunotherapy Data in Melanoma

September 29th 2019

ESMO 2019: Dr. Ramalingam Discusses Confirmatory Data in Advanced NSCLC

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 3

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 2

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 1

September 29th 2019

Dr. Weber on the Updated Analysis of the CheckMate-238 Trial in Melanoma

September 28th 2019

Jeffrey S. Weber, MD, PhD, discusses the updated analysis of the phase III CheckMate-238 trial in patients with resected stage III/IV melanoma.

Evolutionary Approach Drives Melanoma Advancements

September 25th 2019

The treatment landscape changed significantly with the first melanoma clinical trials in 2001, which evaluated the CTLA-4 antibodies ipilimumab (Yervoy) and tremelimumab.

EU Panel Recommends 4-Week Nivolumab Dosing Schedule in Adjuvant Melanoma

September 24th 2019

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of nivolumab at a flat dosing schedule of either 240 mg over 30 minutes every 2 weeks, or 480 mg infused over 60 minutes every 4 weeks, for the adjuvant treatment of patients with melanoma who have involvement of lymph nodes or metastatic disease who have undergone complete resection.

Dr. Flaherty on Second-Line Therapy for BRAF-Mutant Melanoma

September 24th 2019

Keith T. Flaherty, MD, discusses treatment beyond frontline therapy for patients with BRAF-mutant relapsed/refractory melanoma.

Neoadjuvant and Frontline Studies Guide Malignant Melanoma Treatment

September 19th 2019

Five melanoma experts discuss findings from several exciting studies presented at the 2019 ASCO Annual Meeting that are helping to change the way patients with malignant melanoma are treated.

Dr. Nathan on Long-Term Outcomes With Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma

September 19th 2019

Paul D. Nathan, MBBS, PhD, FRCP, consultant medical oncologist, Mount Vernon Cancer Centre, discusses the long-term outcomes with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600-mutant unresectable or metastatic melanoma.

Dr. Sznol Discusses the Combination of Ipilimumab and Nivolumab in Melanoma

September 11th 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the benefits of immunotherapy, specifically the combination of the CTLA-4 inhibitoripilimumab and the PD-1 inhibitor nivolumab, in melanoma.

Dr. Polsky on Validating ctDNA as a Biomarker in BRAF-Mutant Melanoma

September 10th 2019

David Polsky, MD, PhD, Alfred W. Kopf, MD Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology, professor, Department of Pathology, and director, Pigmented Lesion Service, NYU Langone’s Perlmutter Cancer Center, discusses the next steps that have to be taken to validate the clinical utility of circulating tumor DNA (ctDNA) as a biomarker in BRAF-mutant melanoma.

An Instinct for Innovation Drives Robert's Melanoma Research

September 7th 2019

A 2018 Giants of Cancer Care® award winner in Melanoma and Other Skin Cancers, Caroline Robert, MD, PhD, has helped clarify the role of immune therapies in advanced melanoma with her groundbreaking work on clinical trials evaluating anti– CTLA-4 and anti–PD-1 antibodies.

Dr. Robert on Potential of Dabrafenib/Trametinib in Melanoma Brain Metastases

September 6th 2019

Caroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussey, co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University, explains why patients with melanoma and brain metastases were excluded from a trial evaluating the efficacy of dabrafenib plus trametinib.

Encorafenib/Binimetinib Combo Continues to Show Survival Benefit in BRAF-Mutant Melanoma

September 3rd 2019

Encorafenib (Braftovi) plus binimetinib (Mektovi) had superior overall survival and progression-free survival compared with encorafenib or vemurafenib (Zelboraf) alone in patients with BRAF V600–mutant melanoma.